Drug interactions between duvelisib and escitalopram
Interactions between your drugs
Applies to: escitalopram and duvelisib
Consumer information for this interaction is not currently available.
MONITOR: Coadministration with duvelisib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by duvelisib. The interaction may be particularly important for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index. When a single 2 mg oral dose of midazolam, a sensitive CYP450 3A4 substrate, was administered to 14 healthy adult study subjects following multiple doses of duvelisib 25 mg twice daily for 5 days, midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 2.2- and 4.3-fold, respectively.
MANAGEMENT: Caution is advised if duvelisib is used in combination with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever duvelisib is added to or withdrawn from therapy.
- "Product Information. Copiktra (duvelisib)." Verastem, Inc., Needham, MA.
Drug and food interactions
Applies to: escitalopram
Alcohol can increase the nervous system side effects of escitalopram such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with escitalopram. Do not use more than the recommended dose of escitalopram, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.